Decoding HER2 mutations and overexpression in NSCLC

Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Institute of Oncology (VHIO), Barcelona Spain

Enriqueta Felip holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and is currently Section Chief at the Vall d’Hebron University Hospital (HUVH), Head of the Vall d’ Hebron Institute of Oncology’s (VHIO) Thoracic Tumors Group.

Dr. Felip was Associate Professor at the UAB from 2010 to May 2019 and since March 2024 she is a full Professor of Medicine at the same university. She was also a Professor of Medicine at the Universitat de Vic (UVic-UCC) from 2020 – 2024.

Her research focuses on accelerating more effective, personalized and targeted cancer medicines matched to specific molecular alterations identified in patients, unmasking molecular mechanisms of acquired cancer drug resistance, and optimizing immune-based strategies in both advanced and early-stage non-small cell lung cancer.

Enriqueta Felip served as President (2021 – 2023) of the Spanish Society of Medical Oncology (SEOM), and was elected as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) from 2017 to 2021. She has also been a member of the Educational and Scientific Committees of the European Society for Medical Oncology (ESMO), World Conference on Lung Cancer (WCLC), and European Lung Cancer Conference (ELCC).

Dr. Felip serves on the Editorial Boards of various top-tier journals including Annals of Oncology and the Journal of Thoracic Oncology. She has (co) authored approximately 400 peer-reviewed papers with an H-Index of 94.

Disclosures:

Advisory Board / Invited Speaker: Abbvie, Amgen, Astra Zeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, e-Cancer, Eli Lilly, Ellipses Pharma, Genentech / Roche, Gilead, Glaxo Smith Kline, ITEOS Therapuetics, Janssen / Johnson & Johnson, Medical Trends, Medscape, Merck Sharp & Dohme, Peervoice, PER, Pfizer, Pharmamar, Pierre Fabre, Regeneron, Seagen, Tubulis GmbH.

Grifols (independent board member)

Support for meeting attendance and/or travel: AstraZeneca, Johnson & Johnson, Pfizer, Roche.

Head of the Thoracic Group at Institut Gustave Roussy (IGR) (Medical Department of Oncology), Villejuif, France
Professor of medicine at Paris-Saclay University, Paris, France

Prof Planchard’s primary research interests have focused on immunotherapy, genomic analysis and biomarkers and targeted treatments of lung cancers over the last 20 years of his career. He has been involved in more than 200 phase I, II and III clinical trials, with over 300 published articles. Highly Cited Researcher (clarivate) since 2020.
He has been directly involved in trial design, having been international coordinating investigator on trials in the field of thoracic tumours, with the aim to develop a long-term clinical research strategy based on molecular screening.

Prof Planchard participated the latest European recommendations on the management of metastatic non-small-cell lung cancer (ESMO guidelines) and participated in many national and international conferences, including ESMO (European Society for Medical Oncology), ELCC (European Lung Cancer Congress), ASCO (American Society of Clinical Oncology) and WCLC (World Conference of Lung Cancer).

Disclosures:

David Planchard has received fees for consulting, advisory role or Lecture from AstraZeneca, Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Janssen, Pfizer, Roche, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen, GSK

He has participated in clinical trials research as principal  or co-investigator (Institutional financial interests): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, Abbvie, Janssen, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen

He has recieved expenses payments from AstraZeneca, Roche, Novartis, Pfizer, Pierre Fabre.

Hospital Universitario 12 de Octubre, Madrid, Spain

Fernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (USA). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.

Disclosures:

Fernando Lopez-Rios has received grants/research support from Lilly, Roche, Thermo Fisher Scientific

He has received honoraria or consultation fees from Lilly, Roche, Thermo Fisher Scientific, Astra Zeneca, Bayer, Takeda, Janssen, MSD, BMS, Pfizer

Leiden University Medical Center, The Netherlands

Egbert F. Smit graduated from the University of Groningen The Netherlands in 1988. He earned his PhD in 1991 on a thesis entitled “Aspects of Chemotherapy for Lung Cancer”. After obtaining his specialist degree in Pulmonary Medicine he has held various positions in academic medicine and general hospitals. He is currently at the Leiden University Medical Center, Leiden, The Netherlands. Within the department he conducts both (pre-) clinical and translational research regarding all aspects of lung cancer, i.e from carcinogenesis to treatment of metastatic lung cancer. Prof. Smit is author of more than 550 peer reviewed papers and 30 chapters in books and a regular reviewer of all major oncology journals.

Disclosures:

TBC